IL33 and gastric cancer: CAFs have been demonstrated to promote migration and EMT in GC by activating the JAK2/STAT3 signaling pathway through the secretion of IL-6 [5], as well as activation of the ERK1/2-SP1-ZEB2 pathway via the secretion of IL-33 [37].